These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18599182)

  • 21. The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells.
    Talebian L; Fischer DA; Wu J; Channon JY; Sentman CL; Ernstoff MS; Meehan KR
    Transfusion; 2014 Jun; 54(6):1515-21. PubMed ID: 24446786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma.
    Meehan KR; Talebian L; Tosteson TD; Hill JM; Szczepiorkowski Z; Sentman CL; Ernstoff MS
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):129-37. PubMed ID: 22975165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines.
    van Bijnen ST; Withaar M; Preijers F; van der Meer A; de Witte T; Muus P; Dolstra H
    Exp Hematol; 2011 Jul; 39(7):751-62.e1-3. PubMed ID: 21554925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.
    Barber A; Zhang T; Sentman CL
    J Immunol; 2008 Jan; 180(1):72-8. PubMed ID: 18097006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
    Ge X; Li CR; Yang J; Wang GB
    Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.
    Godbersen C; Coupet TA; Huehls AM; Zhang T; Battles MB; Fisher JL; Ernstoff MS; Sentman CL
    Mol Cancer Ther; 2017 Jul; 16(7):1335-1346. PubMed ID: 28500232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NKG2D receptor regulates human effector T-cell cytokine production.
    Barber A; Sentman CL
    Blood; 2011 Jun; 117(24):6571-81. PubMed ID: 21518928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
    Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
    Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.
    Smyth MJ; Swann J; Kelly JM; Cretney E; Yokoyama WM; Diefenbach A; Sayers TJ; Hayakawa Y
    J Exp Med; 2004 Nov; 200(10):1325-35. PubMed ID: 15545356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
    Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
    Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
    Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
    Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Annihilation of Non-small Cell Lung Cancer by NKG2D CAR-T Cells Produced from T Cells from Peripheral Blood of Healthy Donors.
    Jiang J; Liu Y; Zeng Y; Fang B; Chen Y
    J Interferon Cytokine Res; 2023 Oct; 43(10):445-454. PubMed ID: 37819621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
    Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
    J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NKG2D CARs as cell therapy for cancer.
    Sentman CL; Meehan KR
    Cancer J; 2014; 20(2):156-9. PubMed ID: 24667963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NKG2D: A versatile player in the immune system.
    Jelenčić V; Lenartić M; Wensveen FM; Polić B
    Immunol Lett; 2017 Sep; 189():48-53. PubMed ID: 28414183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
    Ding H; Yang X; Wei Y
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
    Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
    Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.